Ombrabulin was an experimental drug candidate discovered by Ajinomoto and further developed by Sanofi-Aventis. Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth.
{{Chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 445300917 | ImageFile = Ombrabulin.svg | ImageClass = skin-invert-image | ImageSize = 200px | ImageAlt = | IUPACName = N1-{2-Methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethen-1-yl]phenyl}-L-serinamide | SystematicName = (2S)-2-Amino-3-hydroxy-N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethen-1-yl]phenyl}propanamide | OtherNames = AVE-8062; AVE-8062A; AC7700; CS-39-L-Ser.HCl |Section1= |Section2= |Section3= }}
Ombrabulin was an experimental drug candidate discovered by Ajinomoto and further developed by Sanofi-Aventis. Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).